New drug combo targets tough cancers in early trial
NCT ID NCT06545942
First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 41 times
Summary
This early-phase study tests a new oral drug called MOMA-313, alone or with another drug (olaparib), in people with advanced solid tumors that have certain DNA repair flaws. The main goals are to check safety and find the right dose. About 220 adults with cancers like prostate, pancreas, breast, or ovarian cancer are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigative Site #101
La Jolla, California, 92093, United States
-
Investigative Site #102
Nashville, Tennessee, 37203, United States
-
Investigative Site #103
New York, New York, 10016, United States
-
Investigative Site #104
Lake Mary, Florida, 32746, United States
-
Investigative Site #105
San Antonio, Texas, 78229, United States
-
Investigative Site #106
New York, New York, 10065, United States
-
Investigative Site #107
Myrtle Beach, South Carolina, 29572, United States
-
Investigative Site #108
Goodyear, Arizona, 85338, United States
-
Investigative Site #109
Philadelphia, Pennsylvania, 19104, United States
-
Investigative Site #110
St Louis, Missouri, 63110, United States
-
Investigative Site #111
San Francisco, California, 94143, United States
-
Investigative Site #112
Fairfax, Virginia, 22031, United States
-
Investigative Site #113
London, United Kingdom
-
Investigative Site #114
Barcelona, Spain
-
Investigative Site #115
Madrid, Spain
-
Investigative Site #116
Barcelona, Spain
-
Investigative Site #117
Manchester, United Kingdom
-
Investigative Site #118
Newcastle upon Tyne, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MOMA-313 (a drug taken by mouth) and olaparib (a PARP inhibitor taken by mouth)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have specific DNA repair problems.
What could go wrong
This is a very early Phase 1 trial focused on safety and dosing, not on proving the drug works. It is small and may not lead to an approved treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.